Plasma Cell Neoplasm/Multiple Myeloma Clinical Trials

• Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004903 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003490 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Melphalan, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003954 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
  ClinicalTrials.gov Identifier: NCT00002630 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00005792 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Combination Chemotherapy With or Without Thalidomide in Treating Patients With Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00005834 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00014508 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00017602 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003603 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00124579 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
  ClinicalTrials.gov Identifier: NCT00258245 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00006890 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004165 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
  
• Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00253578 - Recruiting
  Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma; Refractory Plasma Cell Neoplasm
  
• R115777 in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00021203 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Antineoplaston Therapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003511 - Recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00054353 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004158 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; stage I multiple myeloma; refractory plasma cell neoplasm
  
• Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon alfa in Treating Patients With Advanced Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00006244 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00028600 - Recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003401 - Completed
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00045136 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003399 - Completed
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
  ClinicalTrials.gov Identifier: NCT00258258 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00046852 - Active, not recruiting
  Infection; refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00066638 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00112879 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Arsenic Trioxide in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00017433 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• High-Dose Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Amyloidosis
  ClinicalTrials.gov Identifier: NCT00002810 - Active, not recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
  
• Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00060203 - Active, not recruiting
  stage III multiple myeloma; refractory plasma cell neoplasm
  
• Vaccine Therapy Plus Donor Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00020306 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• CI-994 in Treating Patients With Advanced Myeloma
  ClinicalTrials.gov Identifier: NCT00005624 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Combination Chemotherapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003493 - Completed
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00316940 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00085345 - Recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00317811 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
  ClinicalTrials.gov Identifier: NCT00416897 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm; Renal Failure
  
• Melphalan and Radiation Therapy Followed By Dexamethasone and Thalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00112827 - Recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00227682 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00445692 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
  ClinicalTrials.gov Identifier: NCT00288028 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00017069 - Active, not recruiting
  refractory plasma cell neoplasm; stage II multiple myeloma; stage III multiple myeloma
  
• Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00499577 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Cyclophosphamide and Melphalan Followed By an Autologous Stem Cell Transplant, Dexamethasone, and Thalidomide in Treating Patients With Previously Treated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00293306 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00124605 - Active, not recruiting
  unspecified adult solid tumor, protocol specific; refractory plasma cell neoplasm; stage III multiple myeloma; stage II multiple myeloma
  
• Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone a Previous Autologous or Syngeneic Bone Marrow or Stem Cell Transplant for Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00182663 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Sorafenib in Treating Patients with Metastatic Or Unresectable Solid Tumors, Multiple Myeloma, Or Non-Hodgkin''s Lymphoma with Or Without Impaired Liver Or Kidney Function
  ClinicalTrials.gov Identifier: NCT00118170 - Active, not recruiting
  adult non-Hodgkin''s lymphoma; adult solid tumor; Multiple Myeloma; refractory plasma cell neoplasm
  
• Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00477815 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00305812 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00310024 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00346255 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00432458 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00470093 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00567229 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00568880 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
  ClinicalTrials.gov Identifier: NCT00007995 - Recruiting
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
  
• Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
  ClinicalTrials.gov Identifier: NCT00389701 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Lenalidomide and CCI-779 in Treating Patients With Previously Treated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00398515 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00445484 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00450814 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00477750 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00558896 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00335647 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00482846 - Recruiting
  Drug Toxicity; Mucositis; Multiple Myeloma and Plasma Cell Neoplasm
  
• Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00258206 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00317798 - Recruiting
  Drug Toxicity; Multiple Myeloma and Plasma Cell Neoplasm
  
• Sunitinib in Treating Patients With Relapsed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00514137 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00438841 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00478075 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Total-Body Irradiation, Busulfan, and Interferon alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00003195 - Completed
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
  ClinicalTrials.gov Identifier: NCT00482378 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm; Pain
  
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-Line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00523848 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• PS-341 in Treating Patients With Refractory or Progressive Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00049478 - Active, not recruiting
  refractory plasma cell neoplasm
  
• Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II or Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00217438 - Recruiting
  Drug Toxicity; Multiple Myeloma and Plasma Cell Neoplasm
  
• Activated White Blood Cells in Treating Patients Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Stage II or Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00566098 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00022607 - Completed
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00022282 - Active, not recruiting
  refractory plasma cell neoplasm
  
• Tandem Autologous Stem Cell Transplantation With or Without Maintenance Therapy After the Second Transplantation Compared With Autologous Stem Cell Transplantation Followed By Matched Sibling Allogeneic Stem Cell Transplantation in Patients With Stage II
  ClinicalTrials.gov Identifier: NCT00075829 - Active, not recruiting
  stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Tumor-Infiltrating Lymphocytes in Treating Patients With Persistent or Recurrent B-Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma After a Previous Donor Stem Cell Transplant
  ClinicalTrials.gov Identifier: NCT00445666 - Recruiting
  Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
  
• High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00526734 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
  ClinicalTrials.gov Identifier: NCT00003153 - Active, not recruiting
  refractory plasma cell neoplasm
  
• Follow-Up of Patients With Breast Cancer or Multiple Myeloma Previously Treated on a Gene Therapy Clinical Trial
  ClinicalTrials.gov Identifier: NCT00427726 - Active, not recruiting
  Breast Cancer; Multiple Myeloma and Plasma Cell Neoplasm
  
• Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
  ClinicalTrials.gov Identifier: NCT00054483 - Recruiting
  adult non-Hodgkin's lymphoma; adult solid tumor; Multiple Myeloma; refractory plasma cell neoplasm
  
• Bevacizumab, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Stage II or Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00410605 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Study of Radiation Exposure in Chernobyl Clean-up Workers With Leukemia, Multiple Myeloma, or Myelodysplasia
  ClinicalTrials.gov Identifier: NCT00558974 - Recruiting
  Leukemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
  
• Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00400686 - Recruiting
  Anemia; Multiple Myeloma and Plasma Cell Neoplasm
  
• Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00474929 - Recruiting
  Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
  
• Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
  ClinicalTrials.gov Identifier: NCT00522392 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• VEGF Trap in Treating Patients With Stage II or Stage III Multiple Myeloma That Has Relapsed or Not Responded to Previous Treatment
  ClinicalTrials.gov Identifier: NCT00437034 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
  ClinicalTrials.gov Identifier: NCT00176475 - Recruiting
  Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
  
• Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00047203 - Completed
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• CCI-779 in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00079456 - Completed
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
  
• Vaccine Therapy in Treating Patients Who Have Undergone Autologous Stem Cell Transplant for High-Risk Lymphoma or Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00569309 - Not yet recruiting
  Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Small Intestine Cancer
  
• Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00334932 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00243035 - Completed
  Stage II Multiple Myeloma; Stage III Multiple Myeloma; Refractory Plasma Cell Neoplasm
  
• O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004072 - Completed
  refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00458705 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• 8-Chloro-cyclic Adenosine Monophosphate in Treating Patients With Recurrent or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00004902 - Completed
  stage II multiple myeloma; stage III multiple myeloma; stage I multiple myeloma; refractory plasma cell neoplasm
  
• Vaccine Therapy in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00019097 - Completed
  Stage II Multiple Myeloma; Stage III Multiple Myeloma; Refractory Plasma Cell Neoplasm
  
• Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00378768 - Completed
  Multiple Myeloma and Plasma Cell Neoplasm